abpro

Dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and often life-threatening diseases. Nasdaq: ABP

[abpro @Abpro]

How can next-gen #TCellEngagers better balance safety and efficacy? This Q&A with Drug Discovery Online highlights how thoughtful design principles are expanding the therapeutic window and driving new possibilities in #immunooncology.

https://t.co/HF6rUjuISd

$ABP

[abpro @Abpro]

Abpro unveiled preclinical data for ABP-102/CT-P72 at #AACR25. This HER2 x CD3 #TCellEngager showed potent tumor killing, reduced cytokine release & improved tolerability—supporting its potential as best-in-class.

More info: https://t.co/KRY6n294Dk

$ABP

[abpro @Abpro]

Abpro will present the first preclinical data for ABP-102/CT-P72, a tetravalent HER2 x CD3 #TCellEngager, at #AACR25. Join us in the New Drugs on the Horizon session on April 27 as we showcase its potential in #HER2 positive cancers.

More info: https://t.co/i5oFbDi93f

$ABP

[abpro @Abpro]

As of today, our new domain is https://t.co/gVYnNpv6jk. Please update your records, as our old domain is no longer active. All company emails will now come from https://t.co/gVYnNpv6jk, but the format before the @ remains unchanged. $ABP

[abpro @Abpro]

Our team will be at #JPM25 discussing our advancement of nextgen #TCellEngagers to help patients battling solid tumors, breast, gastric, liver, colorectal and others, and our mission to impact the future of #immunotherapy. Contact [email protected] to schedule a 1X1 with us.

#JPMWeek

[abpro @Abpro]

We rang the @Nasdaq bell to celebrate becoming a public company! The funding raised through our business combination supports advancing our nextgen antibody therapies for cancer, ophthalmology, and infectious diseases.

Learn more: https://t.co/6kTLXFSh4y

$ABP #Tcellengagers